Discipline

Medical Oncologist

Research Department

Medical Oncology

Interests

Acquired resistance to erlotinib, Genotype-defined subsets of lung cancer, Familial lung cancer syndromes

Biography

I am a thoracic oncologist with two primary areas of research. Through collaborations with molecular pathologists and laboratory researchers, I am interested in identifying subpopulations of lung cancer with unique clinical and molecular characteristics. For example, we have recently identified that lung cancer patients with T790M-mediated acquired resistance to erlotinib (Tarceva) have a favorable outcome, likely indicating a need for a unique therapeutic strategy.

Additionally, I perform research with colleagues in radiology and medical physics to explore better ways of analyzing response and progression in clinical trials and correlative research. In a recent analysis, we showed that volumetric CT measurement after only 3 weeks of gefitinib is able to accurately distinguish which lung cancers harbor sensitizing mutations. Multiple analyses of industry and cooperative group imaging data are ongoing through collaborations with Lawrence Schwartz, Chair of Radiology, Columbia University. 

Background

Board Certification
Internal Medicine, 2008
Medical Oncology, 2010

Fellowship
Memorial Sloan-Kettering Cancer Center, Medical Oncology, 2011

Residency
Massachusetts General Hospital, Internal Medicine, 2008

Medical School
University of Chicago Pritzker School of Medicine, 2005

Recent Awards

• Young Investigator Award, ASCO Cancer Foundation, 2010; Merit Award, ASCO Annual Meeting, 2010, 2010